Pompe’s disease

A rare autosomal recessive progressive neuromuscular disease.

A metabolic myopathy caused by a deficiency of acid alpha glucosidase, an enzyme that degrades lysosomal glycogen.

Characterized by progressive muscle weakness and loss of respiratory function, leading to early death.

In the classic infantile form glycogen is deposited in the heart, skeletal and respiratory muscles causing severe cardiomyopathy, hypotonia, and respiratory failure, leading to death within the first year of life.

In children and adults the disease is variability in disease progression.

Most deaths due to respiratory failure.

Treatment with enzyme replacement therapy with alglucosidase alfa.

Infants treated with alglucosidase alfa have improvement in survival and motor outcomes and use in children 8 years or older was associated with improved walking and stabilization in pulmonary functionover 18 months (van der Ploeg AT).

People with late onset Pompe disease have genetic variants that create a  deficiency of acid alpha-glucosidase, an enzyme that breaks down glycogen into glucose for energy.
Without this enzyme glycogen build up damages muscles, especially heart and skeletal  muscle which can lead to death from heart or respiratory failure.

Avalglucosidase approved based on the results of a randomized phase 3 trial manifesting improved six minute walking tests.

Leave a Reply

Your email address will not be published. Required fields are marked *